About BBIO Dividend Returns
BridgeBio Pharma, Inc. (BBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of BBIO over the past year?
BridgeBio Pharma, Inc. (BBIO) delivered a return of 90.49% over the past year. Since BBIO does not currently pay dividends, the total return equals the price-only return.
Q2How much would $10,000 invested in BBIO be worth today?
A $10,000 investment in BridgeBio Pharma, Inc. one year ago would be worth $19,049 today, representing a gain of $9,049.
Q3Does BBIO pay dividends?
BridgeBio Pharma, Inc. (BBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BBIO, the total return equals the price-only return.
Q4Did BBIO beat the S&P 500?
Yes, BridgeBio Pharma, Inc. (BBIO) outperformed the S&P 500 by 75.04 percentage points over the past year. BBIO delivered a total return of 90.49%, compared to the S&P 500's 15.45%. This 75.04pp alpha means investors in BBIO earned more than a passive S&P 500 index fund.
Q5What is BBIO's worst drawdown?
BridgeBio Pharma, Inc. (BBIO) experienced a maximum drawdown of -20.25% over the past year, declining from its peak on 2026-01-22 to its trough on 2026-02-05. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is BBIO's long-term total return over 10, 20, or 30 years?
BridgeBio Pharma, Inc. (BBIO) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 141.3% (9.2% CAGR) — $10,000 would have grown to $24,131. Over 20 years: 141.3% total return (4.5% CAGR) — $10,000 → $24,131. Over 30 years: 141.3% total return (3.0% CAGR) — $10,000 → $24,131. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was BBIO's best and worst year?
BridgeBio Pharma, Inc.'s best calendar year was 2023 with a total return of 463.0%. Its worst year was 2021 with a total return of -73.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 536.8 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).